Tardive dyskinesia and other movement disorders secondary to aripiprazole

Movement Disorders

Volumn 26, Issue 1, 2011, Pages 147-152

  Peña, Maria Sierra ^a   Yaltho, Toby C ^a   Jankovic, Joseph ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Antipsychotics; Aripiprazole; Neuroleptics; Tardive dyskinesia; Tetrabenazine

Indexed keywords

ARIPIPRAZOLE; HALOPERIDOL; MESORIDAZINE; METOCLOPRAMIDE; OLANZAPINE; QUETIAPINE; RISPERIDONE; TETRABENAZINE;

AKATHISIA; ARTICLE; BIPOLAR DISORDER; CORRELATION ANALYSIS; DISEASE ASSOCIATION; DRUG WITHDRAWAL; FOLLOW UP; HUMAN; MEDLINE; MOTOR DYSFUNCTION; PARKINSONISM; PRIORITY JOURNAL; SEX DIFFERENCE; SYSTEMATIC REVIEW; TARDIVE DYSKINESIA; TREATMENT DURATION;

ADULT; AGED; ANTIPSYCHOTIC AGENTS; DATABASES, FACTUAL; FEMALE; HUMANS; MALE; MIDDLE AGED; MOVEMENT DISORDERS; PIPERAZINES; QUINOLONES;

EID: 79951470800     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.23402     Document Type: Article

References (60)

1. Schoenecker M. Ein Eigentsumliches syndrom im oralen bereich bei Magaphen Applikation. Nervenarzt 1957; 28: 35-37.
2. Schwartz T, Raza S. Aripiprazole (abilify) and tardive dyskinesia. P T 2008; 33: 32-34.
3. Jordan S, Koprivica V, Chen R, Tottori K, Kikuchi T, Altar CA. The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT1A receptor. Eur J Pharmacol 2002; 441: 137-140.
4. Keck PE, Jr, Marcus R, Tourkodimitris S, et al. A placebo-controlled, double-blind study of the efficacy and safety of aripiprazole in patients with acute bipolar mania. Am J Psychiatry 2003; 160: 1651-1658.
5. Nelson JC, Thase ME, Trivedi MH, et al. Safety and tolerability of adjunctive aripiprazole in major depressive disorder: a pooled post hoc analysis (studies CN138-139 and CN138-163). Prim Care Companion J Clin Psychiatry 2009; 11: 344-352.
6. Fahn S, Jankovic J. The tardive syndromes. In: Principles and practice of movement disorder. Churchill Livingstone Elsevier: Philadelphia; 2007. p 491-492.
7. Jankovic J. Treatment of hyperkinetic movement disorders. Lancet Neurol 2009; 8: 844-856.
8. Abbasian C, Power P. A case of aripiprazole and tardive dyskinesia. J Psychopharmacol 2009; 23: 214-215.
9. Caykoylu A, Ekinci O, Yilmaz E. Resolution of risperidone-induced tardive dyskinesia with a switch to aripiprazole monotherapy. Prog Neuropsychopharmacol Biol Psychiatry 2009; 33: 571-572.
10. Evcimen YA, Evcimen H, Holland J. Aripiprazole-induced tardive dyskinesia: the role of tamoxifen. Am J Psychiatry 2007; 164: 1436-1437.
11. Hall DA, Agarwal P, Griffith A, Segro V, Seeberger LC. Movement disorders associated with aripiprazole use: a case series. Int J Neurosci 2009; 119: 2274-2279.
12. Hettema JM, Ross DE. A case of aripiprazole-related tardive akathisia and its treatment with ropinirole. J Clin Psychiatry 2007; 68: 1814-1815.
13. Lim HK, Pae CU, Lee C, Lee CU. Tardive dystonic symptoms associated with aripiprazole treatment. Prog Neuropsychopharmacol Biol Psychiatry 2008; 32: 589-590.
14. Lungu C, Aia PG, Shih LC, Esper CD, Factor SA, Tarsy D. Tardive dyskinesia due to aripiprazole: report of 2 cases. J Clin Psychopharmacol 2009; 29: 185-186.
15. Maytal G, Ostacher M, Stern TA. Aripiprazole-related tardive dyskinesia. CNS Spectr 2006; 11: 435-439.
16. Oommen E, Chand PK, Sharma PS. Aripiprazole-induced tardive dystonia. Prim Care Companion J Clin Psychiatry 2006; 8: 378-379.
17. Pinninti NR, Mago R, Adityanjee Tardive dystonia-associated prescription of aripiprazole. J Neuropsychiatry Clin Neurosci 2006; 18: 426-427.
18. Wang LJ, Ree SC, Chen CK. Courses of aripiprazole-associated tardive dyskinesia: report of two cases. Prog Neuropsychopharmacol Biol Psychiatry 2009; 33: 743-744.
19. Zaidi SH, Faruqui RA. Aripiprazole is associated with early onset of tardive dyskinesia like presentation in a patient with ABI and psychosis. Brain Inj 2008; 22: 99-102.
20. Woerner MG, Kane JM, Lieberman JA, et al. The prevalence of tardive dyskinesia. J Clin Psychopharmacol 1991; 11: 34-42.
21. Jankovic J. Tardive syndromes and other drug-induced movement disorders. Clin Neuropharmacol 1995; 18: 197-214.
22. Tarsy D, Baldessarini RJ. Epidemiology of tardive dyskinesia: is risk declining with modern antipsychotics? Mov Disord 2006; 21: 589-598.
23. Dratcu L, Olowu P, Hawramy M, Konstantinidou C. Aripiprazole in the acute treatment of male patients with schizophrenia: effectiveness, acceptability, and risks in the inner-city hospital setting. Neuropsychiatr Dis Treat 2006; 2: 191-197.
24. Lykouras L, Rizos E, Gournellis R. Aripiprazole in the treatment of tardive dyskinesia induced by other atypical antipsychotics. Prog Neuropsychopharmacol Biol Psychiatry 2007; 31: 1535-1536.
25. McIntyre RS, Soczynska JK, Woldeyohannes HO, Miranda A, Konarski JZ. Aripiprazole: pharmacology and evidence in bipolar disorder. Expert Opin Pharmacother 2007; 8: 1001-1009.
26. Sharma A, Ramaswamy S, Dewan VK. Resolution of ziprasidone-related tardive dyskinesia with a switch to aripiprazole. Prim Care Companion J Clin Psychiatry 2005; 7: 36.
27. Tarsy D, Baldessarini RJ. Behavioural supersensitivity to apomorphine following chronic treatment with drugs which interfere with the synaptic function of catecholamines. Neuropharmacology 1974; 13: 927-940.
28. Klawans HL, Carvey P, Tanner CM, Goetz CG. The pathophysiology of tardive dyskinesia. J Clin Psychiatry 1985; 46(4 Pt 2): 38-41.
29. Seeman P. Tardive dyskinesia, dopamine receptors, and neuroleptic damage to cell membranes. J Clin Psychopharmacol 1988; 8(4 Suppl): 3S-9S.
30. Cardoso F, Jankovic J. Dystonia and dyskinesia. Psychiatr Clin North Am 1997; 20: 821-838.
31. Tamminga CA, Woerner MG. clinical course and cellular pathology of tardive dyskinesia. In: Davis KL, Charney D, Coyle JT, et al., editors. Neuropsychopharmacology: the fifth generation. Philadelphia: Lippincott Williams & Wilkins; 2002. p 1831-1841.
32. Marchand WR, Dilda V. New models of frontal-subcortical skeletomotor circuit pathology in tardive dyskinesia. Neuroscientist 2006; 12: 186-198.
33. Gentile S. Extrapyramidal adverse events associated with atypical antipsychotic treatment of bipolar disorder. J Clin Psychopharmacol 2007; 27: 35-45.
34. Seeman P, Tallerico T. Antipsychotic drugs which elicit little or no parkinsonism bind more loosely than dopamine to brain D2 receptors, yet occupy high levels of these receptors. Mol Psychiatry 1998; 3: 123-134.
35. Correll CU, Schenk EM. Tardive dyskinesia and new antipsychotics. Curr Opin Psychiatry 2008; 21: 151-156.
36. Albers LJ, Ozdemir V. Pharmacogenomic-guided rational therapeutic drug monitoring: conceptual framework and application platforms for atypical antipsychotics. Curr Med Chem 2004; 11: 297-312.
37. Beasley CM, Dellva MA, Tamura RN, et al. Randomised double-blind comparison of the incidence of tardive dyskinesia in patients with schizophrenia during long-term treatment with olanzapine or haloperidol. Br J Psychiatry 1999; 174: 23-30.
38. Tollefson GD, Beasley CM, Jr, Tamura RN, Tran PV, Potvin JH. Blind, controlled, long-term study of the comparative incidence of treatment-emergent tardive dyskinesia with olanzapine or haloperidol. Am J Psychiatry 1997; 154: 1248-1254.
39. Lieberman JA, Tollefson G, Tohen M, et al. Comparative efficacy and safety of atypical and conventional antipsychotic drugs in first-episode psychosis: a randomized, double-blind trial of olanzapine versus haloperidol. Am J Psychiatry 2003; 160: 1396-1404.
40. Correll CU, Leucht S, Kane JM. Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies. Am J Psychiatry 2004; 161: 414-425.
41. Kenney C, Hunter C, Davidson A, Jankovic J. Metoclopramide, an increasingly recognized cause of tardive dyskinesia. J Clin Pharmacol 2008; 48: 379-384.
42. Tenback DE, van Harten PN, Slooff CJ, Belger MA, van Os J. Effects of antipsychotic treatment on tardive dyskinesia: a 6-month evaluation of patients from the European Schizophrenia Outpatient Health Outcomes (SOHO) Study. J Clin Psychiatry 2005; 66: 1130-1133.
43. Pierre JM. Extrapyramidal symptoms with atypical antipsychotics: incidence, prevention and management. Drug Saf 2005; 28: 191-208.
44. Nasrallah HA. Focus on lower risk of tardive dyskinesia with atypical antipsychotics. Ann Clin Psychiatry 2006; 18: 57-62.
45. Woods SW, Morgenstern H, Saksa JR, Walsh BC, Sulivan MC, Money R, Hawkins KA, Gueorguieva RV, Glazer WM. Incidence of tardive dyskinesia with atypical versus conventional antipsychotic medications: a prospective cohort study. J Clin Psychiatry 2010; 71: 463-474.
46. Meyboom RH, Ferrari MD, Dieleman BP. Parkinsonism, tardive dyskinesia, akathisia, and depression induced by flunarizine. Lancet 1986; 2: 292.
47. Leo RJ. Movement disorders associated with the serotonin selective reuptake inhibitors. J Clin Psychiatry 1996; 57: 449-454.
48. Burris KD, Molski TF, Xu C, et al. Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors. J Pharmacol Exp Ther 2002; 302: 381-389.
49. Jankovic J, Beach J. Long-term effects of tetrabenazine in hyperkinetic movement disorders. Neurology 1997; 48: 358-362.
50. Kenney C, Hunter C, Jankovic J. Long-term tolerability of tetrabenazine in the treatment of hyperkinetic movement disorders. Mov Disord 2007; 22: 193-197.
51. Mejia NI, Jankovic J. Tardive dyskinesia and withdrawal emergent syndrome in children. Expert Rev Neurother 2010; 10: 893-901.
52. Chen CK, Wu JH. Improvement of risperidone-related tardive parkinsonism with a switch to aripiprazole. Prog Neuropsychopharmacol Biol Psychiatry 2009; 33: 1279-1280.
53. Duggal HS. Aripiprazole-induced improvement in tardive dyskinesia. Can J Psychiatry 2003; 48: 771-772.
54. Grant MJ, Baldessarini RJ. Possible improvement of neuroleptic-associated tardive dyskinesia during treatment with aripiprazole. Ann Pharmacother 2005; 39: 1953.
55. Kantrowitz JT, Srihari VH, Tek C. Resolution of tardive dyskinesia after addition of aripiprazole to haloperidol depot. J Clin Psychopharmacol 2007; 27: 525-526.
56. Osorio RS, Agüera-Ortiz L, Hurtado de Mendoza A, Ramos I, Palomo T. Treatment of Tardive Dyskinesia with Aripiprazole. Neurotox Res 2010; 17: 432-434.
57. Rajarethinam R, Dziuba J, Manji S, Pizzuti A, Lachover L, Keshavan M. Use of aripiprazole in tardive dyskinesia: an open label study of six cases. World J Biol Psychiatry 2009; 10(4 Pt 2): 416-419.
58. Shan JC, Tseng MC. Improvement in Pisa syndrome and tardive dyskinesia following aripiprazole treatment. J Neuropsychiatry Clin Neurosci 2009; 21: 350-351.
59. Witschy JK, Winter AS. Improvement in tardive dyskinesia with aripiprazole use. Can J Psychiatry 2005; 50: 188.
60. Dayalu P, Chou KL. Antipsychotic-induced extrapyramidal symptoms and their management. Expert Opin Pharmacother 2008; 9: 1451-1462.